AIM WINNERS & LOSERS: Yourgene surges on takeover by Novacyt
3rd Jul 2023 10:48
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday. Read More
(Alliance News) - Verici Dx PLC on Monday said it received successful results from its clinical study of Clarava that demonstrate it as a test capable of informing a clear, actionable response from clinicians. Read More
(Alliance News) - The following is a round-up of updates on exposure to Silicon Valley Bank by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - Verici Dx PLC on Thursday said it won two key patents for its RNA signature biomarker tests Tutiva and Clarava in the US. Read More
Verici Dx PLC - Cardiff-based developer of clinical diagnostics for organ transplant - Successfully progresses its registration status to compliance certification to the Centers for Medicare & Medicaid for its commercial clinical operations in 45 US states. This follows the inspection by CMS of the company's US clinical laboratory based in Franklin, Tennessee. Verici Dx will now proceed with its plan towards full accreditation in the remaining five states. Verici Dx explains the milestone of certification is also a key requirement to obtaining insurance reimbursement coverage under Medicare under the local coverage determination application being submitted this year. Company also intends to expand commercialisation of its advanced kidney transplant service offerings, including Tutivia. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday. Read More
Verici Dx PLC - Tennessee-based developer of clinical diagnostics for organ transplants - Rebrands its post-transplant blood test focused on acute rejection, Tuteva, to Tutivia. Tutivia will be the first test commercialised on the Verici transplant biomarker platform, with a soft commercial launch in the US expected later in 2022. Read More
(Alliance News) - Verici Dx PLC on Wednesday reported a widened loss in the first half but the firm said it is geared up for a commercialisation push to start generating revenue. Read More
(Alliance News) - Verici Dx PLC on Tuesday announced the successful outcome of a clinical validation study of its Clarava test. Read More
EKF Diagnostics Holdings PLC - Cardiff-based diagnostics and central laboratory assay maker - Distributes 9.1 million shares in Verici Dx PLC to shareholders through distribution in specie. In March, EKF confirmed it would distribute to its own shareholders shares in Verici it would receive for participating in the clinical diagnostics company's fundraising. Read More
(Alliance News) - Verici Dx PLC on Tuesday reported further data from a clinical validation study evaluating Tuteva, the company's post-transplant blood test focused on acute rejection. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
Verici Dx PLC - Tennessee-based developer of clinical diagnostics for organ transplants - Confirms equity issue raises full target of GBP10.0 million from the sale of 28.6 million new shares at 35 pence each. The new shares represent 20% of Verici Dx's total beforehand. T Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
Verici Dx PLC - Tennessee-based developer of clinical diagnostics for organ transplants - Plans to raise at least GBP10.0 million from the sale of 28.6 million new shares at 35 pence each. The fundraise is being run on Friday as an accelerated bookbuild by Singer Capital Markets. Verici DX says the funds will be used to accelerate the commercialisation of its two lead products, Clarava and Tuteva, and to continue the development of third product Protega. The results of the fundraise will be announced later Friday. Read More
(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Friday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Friday and not separately reported by Alliance News: Read More